NERV stock forecast
Our latest prediction for Minerva Neurosciences, Inc.'s stock price was made on the June 24, 2019 when the stock price was at 5.93$.
In the short term (2weeks), NERV's stock price should underperform the market by -0.40%. During that period the price should oscillate between -11.89% and +18.19%.
In the medium term (3months), NERV's stock price should outperform the market by 1.91%. During that period the price should oscillate between -22.52% and +36.80%.Get email alerts
Create a solid portfolio with NERV
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.75$ per share.
The book value per share is 2.85$
Three months stock forecastJune 24, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|